COMP <GO>
COO vs JNJ // EV/EBITDA & P/E VALUATION
The Cooper Companies Inc. (NASDAQ) VS. Johnson & Johnson (NYSE) • 15-METRIC TALLY: COO 3
— JNJ 10
▲ EV/EBITDA & P/E VALUATION LEADER: COO
LAST: $59.55 (-1.31%) • MKT CAP: $11.47B
valuation
13.3x
LAST: $273.20 (-0.73%) • MKT CAP: $662.49B
valuation
18.5x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (COO VS. JNJ)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | COO | JNJ | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 65.50% | 67.90% | -2.40 | JNJ | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 5.30% | 25.50% | -20.20 | JNJ | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | 13.3x | 18.5x | -5.20 | COO | /valuation <GO> |
| Free Cash Flow Yield | 3.78% | 2.97% | +0.81 | COO | /fcf-yield <GO> |
| Operating Margin | 16.70% | 34.70% | -18.00 | JNJ | /operating-margins <GO> |
| Net Profit Margin | 9.20% | 28.50% | -19.30 | JNJ | /net-margins <GO> |
| Revenue Growth (YoY) | 5.10% | 6.00% | -0.90 | JNJ | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 3.13 | 5.59 | -2.46 | JNJ | /balance-sheet <GO> |
| Piotroski F-Score Quality | 8/9 | 8/9 | 0.00 | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 6.90% | 7.20% | -0.30 | COO | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 52.5 | 60.4 | -7.83 | JNJ | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.01 | 1.08 | -0.07 | JNJ | /macro-sensitivity <GO> |
| Forward P/E Multiple | 28.5x | 23.0x | +5.50 | JNJ | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $11.47B | $662.49B | -$651.02B | JNJ | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | COO REV | JNJ REV | COO GROSS % | JNJ GROSS % | COO FCF | JNJ FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $4.09B | $94.19B | 65.5% | 67.9% | $433.7M | $19.70B |
| FY 2024 | $3.90B | $88.82B | 66.6% | 69.1% | $288.1M | $19.84B |
| FY 2023 | $3.59B | $85.16B | 44.0% | 44.0% | $445.8M | $18.96B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
COO // BETA 1.01
JNJ // BETA 1.08